New "Druggable" Target for Sporadic Parkinson's Disease
News Jun 03, 2016
The research, published in the journal Neurobiology of Disease identifies new targets that show promise for drug development for an incurable condition that affects as many as one million Americans.
The study focused on parkin – a protein involved in the degradation and purging of both damaged proteins and mitochondria via a process known as lysosomal autophagy. Mutations of parkin are linked to a rare familial form of PD, whereby the cell loses the ability to recycle its internal garbage. PD is characterized by the accumulation of damaged proteins and mitochondria in the area of the brain where the neurotransmitter dopamine is produced.
In this study scientists, led by Buck faculty Julie Andersen, PhD, showed that oxidative stress, which is one of the main drivers of sporadic PD, affected the parkin protein in the same way that genetic mutations do. “This gives us a significant insight into sporadic PD which accounts for 95 percent of all cases of the disease,” said Andersen. “We also determined that the signaling pathway involved in the molecular dysfunction is a good target for drug development.”
The pathway involves two master regulatory proteins, PGC-1alpha which affects the synthesis of new mitochondria and TFEB which is involved in breaking down old mitochondria. Both are down-regulated following oxidative stress. When scientists genetically increased the expression of PGC-1alpha in the affected mice, mitochondrial function was restored, preventing the degeneration of dopaminergic neurons affected by PD.
Researchers in the Andersen and Lithgow labs are now screening compounds in human cell culture and in nematode worms that have been genetically engineered to develop PD-like characteristics. The goal is to identify compounds that target the pathway and prevent the neurotoxic damage associated with the disease.
Disease-Fighting 'Warheads' Hidden in BacteriaNews
Bacteria found in soil may harbor a potential game-changer for drug design. A new study by Scripps Research, published today in Nature Communications, suggests scientists could build better drugs by learning from bacteria-derived molecules called thiocarboxylic acids.READ MORE
Exploring Challenges in the Synthesis of Pharmaceutical DrugsNews
This summer, Wendell and Loretta Hess Professor of Chemistry Ram Mohan will travel to India and Hong Kong to deliver a series of post-graduate workshops on advanced concepts in organic synthesis.
His workshop “Advanced Concepts in the Synthesis of Pharmaceutical Drugs” at the Indian Institute of Technology Indore will explore the unique, real-world challenges in the pharmaceutical industry to synthesize drugs that are both commercially viable and eco-friendly.
Modern Alchemists are Making Chemistry GreenerNews
Ancient alchemists tried to turn lead and other common metals into gold and platinum. Modern chemists in Paul Chirik’s lab at Princeton are transforming reactions that have depended on environmentally unfriendly precious metals, finding cheaper and greener alternatives to replace platinum, rhodium and other precious metals in drug production and other reactions.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018